



FEVER IN INFANTS LESS THAN 60 DAYS

ALGORITHM



ALGORITHM- HSV Testing



ALGORITHM- Admission




TABLE OF CONTENTS

[Algorithm](#)

[Algorithm- HSV Testing](#)

[Algorithm- Admission](#)

[Target Population](#)

[Background | Definitions](#)

[Initial Evaluation](#)

[Laboratory Studies | Imaging](#)

[Therapeutics](#)

[Disposition](#)

[References](#)

[Clinical Improvement Team](#)

TARGET POPULATION

Inclusion Criteria

- Age less than or equal to (\leq) 60 days
- Fever (greater than or equal to (\geq) 38.0°C (100.4° F)) or less than ($<$) 36.0°C (96.8° F)
- Parental report of tactile fever should be considered
- Gestational age greater than ($>$) 37 weeks AND weight greater than ($>$) 2000 grams

Exclusion Criteria

- Need for immediate critical care
- Chronic or underlying illness
- Immunocompromised

BACKGROUND | DEFINITIONS

- Serious Bacterial Illness (SBI):
 - Includes bacteremia/sepsis, meningitis, and urinary tract infections (UTIs)
 - Febrile infants less than 28 days are at higher risk of SBIs
 - For febrile infants, no universal risk stratification currently exists to identify SBI either by clinical examination, routine laboratory tests, biomarkers or selection criteria.^{2,3}
- Rectal temperature correlates most closely with core body temperature⁵
- Infants with otitis media are at the same risk of bacteremia as patients without an otitis media
- Infants with enterovirus identified in cerebrospinal fluid (CSF) are lower risk for SBI, have decreased length of stay, exposure to antibiotics, and hospital costs.^{6,7,8,9}

Table 1: Incidence of SBI in infants⁴

	Incidence of infection in febrile infants 7-90 days
Urinary Tract Infection (UTI)	17%**
Bacteremia	2%
Meningitis	0.9%

**10% of patient with UTI will have bacteremia

INITIAL EVALUATION

Thorough history and physical examination including these high-risk considerations:

- Maternal history of intra-partum fever, antibiotic treatment, group B strep infection
- Infant history of prior antibiotic treatment, hospitalization longer than mother, previous hospitalization, unexplained hyperbilirubinemia, prematurity (less than 37 weeks), temp greater than 38.5°C¹⁰

LABORATORY STUDIES | IMAGING

Procalcitonin^{11,12,13}

- For well-appearing infants 29-60 days, a normal procalcitonin lowers the risk of serious bacterial infection. (Can consider discharge home without antibiotics after blood and urine cultures are obtained.)
- An elevated procalcitonin warrants further investigation for serious bacterial infection and antibiotic initiation while awaiting blood, urine, and CSF cultures.

Traumatic/Dry Lumbar Punctures

- Interpretation of traumatic or dry taps can be difficult. In general, traumatic lumbar punctures (LPs) are defined as greater than 500 RBCs/hpf and correcting with ratios can be inaccurate. The decision regarding whether or not to treat for meningitis in these situations is influenced by degree of fever, degree of illness, other laboratory studies, cultures, age of the infant, and other factors.

Neonatal Herpes Simplex Virus (HSV)^{14,15}

- See algorithm on *page 2*
- Early diagnosis and treatment improves outcomes; untreated infections often result in death or serious morbidity
- The vast majority of neonatal HSV cases occur in infants less than 28 days, with few cases reported greater than 6 weeks of age
- Skin, eye, and mucous membrane infection typically presents at 7-14 days of age, CNS infection at 14-21 days, and disseminated disease at 5-12 days

Meningitis Encephalitis Panel (MEP)

- MEP rapidly tests CSF for 14 common causes of central nervous system (CNS) infection but does not rule out meningitis due to other pathogens.
- MEP should be ordered if concern for HSV and enterovirus/parechovirus. If only suspicious of a single organism (or MEP unavailable), consider PCR testing for individual organism(s).
- Consider MEP for enterovirus and parechovirus testing regardless of CSF white blood cell count (WBC) (as most lack pleocytosis).

Viral Testing¹³

Viral testing indicated in select infants based on season and clinical presentation and *only* if results will change management.

- Consider flu PCR during influenza season.
- Consider Gastrointestinal Pathogen Panel if bloody diarrhea.

Additional diagnostic studies if indicated:

- Basic metabolic profile (BMP) if concern of dehydration, electrolyte disturbance or if starting acyclovir

THERAPEUTICS

Antibiotic Recommendations

- Obtain all cultures prior to antibiotic administration if possible
- IV route of antibiotic administration is preferred
- If enterovirus or parechovirus is identified in a well-appearing infant, you can discontinue antibiotics
- Duration of antibiotic therapy varies based on diagnosis, culture results, and clinical improvement of the infant

	Focus	Age 0-28 days	Age 29-60 days
EMPIRIC THERAPY	Suspected UTI or SBI	ampicillin (see dosing below) AND gentamicin (see dosing below)	ceftriaxone (see dosing below)
	Suspected Meningitis or abnormal CSF	ampicillin (see dosing below) AND cefotaxime (see dosing below)	vancomycin (see dosing below) AND ceftriaxone (see dosing below)
	Suspected HSV	acyclovir (see dosing below)	

- Dosing Recommendations (updated 12/2019):
 - Ampicillin:
 - Suspected UTI/SBI:
 - Body weight greater than 2 kg
 - 0-28 days: 50 mg/kg every 8 hours
 - 29-60 days: 50 mg/kg every 6 hours
 - Suspected meningitis or abnormal CSF:
 - Less than or equal to 7 days: 100 mg/kg/dose every 8 hours
 - 8-60 days: 75 mg/kg/dose every 6 hours
 - Gentamicin:
 - 35+ weeks
 - Less than or equal to 7 days: 4 mg/kg every 24 hours
 - 8-60 days: 5 mg/kg every 24 hours

- Cefotaxime:
 - 50 mg/kg/dose at the following intervals:
 - q8-12 h: Less than/equal to 7 days old
 - q6-8h: Greater than 7 days old
- Vancomycin:
 - > 28 weeks
 - SCr < 0.7: 15 mg/kg q12
 - SCr 0.7-0.9: 20 mg/kg q24
 - SCr 1-1.2: 15 mg/kg q24
 - SCr 1.3-1.6: 10 mg/kg q24
 - SCr > 1.6: 15 mg/kg Q48
- Ceftazidime:
 - 50 mg/kg/dose at the following intervals:
 - q8-12h: Less than/equal to 7 days old
 - q8h: Greater than 7 days old
- Ceftriaxone:
 - Infant must be older than 28 days to use
 - Sepsis/UTI: 50 mg/kg Q24H
 - Meningitis/Abnormal CSF: 100 mg/kg Q24H -**OR**- 50 mg/kg Q12H
- Acyclovir:
 - 20 mg/kg/dose every 8 hours

Alternative to cefotaxime during medication shortage for infants less than or equal to 28 days old: ceftazidime 50 mg/kg/dose every 8 hours, max 2000 mg/dose

Outpatient Antibiotic Recommendations for Urinary Tract Infection (UTI)

- For neonates and infants less than 2 months of age with presumed UTI, initiate empiric parenteral antibiotics. Neonates less than 1 month of age must receive parenteral therapy, due to inadequate drug absorption, immature immune system and increased dissemination of infection¹⁸. Bacteremia secondary to acute pyelonephritis occurs in 6.1-22.7% of children less than 2 months of age¹⁹.
 - For infants 29-60 days old with uncomplicated bacterial UTI and close follow-up, parenteral antibiotics may be switched to oral antibiotics at the discretion of the provider after clinical improvement.
 - Oral antibiotics should be chosen based on gram stain, culture results and local antibiotic susceptibility patterns.

Additional Antibiotic Considerations

- 29-60 days: Antibiotics are not indicated if laboratory results are within normal limits, no concern of SBI/sepsis, or high index suspicion of viral etiology^{20,13}. Select site-specific treatment for minor focal infection in well-appearing child

DISPOSITION

Admission

- See Admission Algorithm on *page 3*
- Additional considerations for admission:
 - Unable to confirm follow up in less than 24 hours
 - Lack of telephone or transportation
 - Inadequate home resources
 - Caretaker unable to provide care
 - Notify primary care provider (PCP) and admitting physician

Discharge Home

- If the patient is diagnosed with a treatable infection, then manage as appropriate
- Discharge home with good follow up if patient is well-appearing and cultures negative at 24-36 hours, workup for age and appearance is complete and reassuring (including HSV if appropriate).
 - If well appearing infant greater than 7 days with enterovirus or parechovirus identified, can discharge earlier

REFERENCES

1. Smitherman H, Macias C. Febrile infant (younger than 90 days of age): Definition of fever. <http://www.uptodate.com>. January 3, 2017. Accessed December 19, 2017.
2. Cuello Garcia CA, Tamez Gomez L, Valdez Ceballos J. [Total white blood cell count, erythrocytation rate and C-reactive protein for the detection of serious bacterial infections in 0- to 90-day-old infants with fever without a source]. *An Pediatr (Barc)* 2008;68:103-9.
3. Gerdes JS. Diagnosis and management of bacterial infections in the neonate. *Pediatr Clin North Am* 2004;51:939-59, viii-ix.
4. Greenhow TL, Hung YY, Herz AM, et al. The changing epidemiology of serious bacterial infections in young infants. *Pediatr Infect Dis J* 2014;33(6):595-9.
5. Claudius I, Baraff LJ. Pediatric emergencies associated with fever. *Emerg Med Clin North Am* 2010;28:67-84, vii-viii.
6. Byington, C. L., et al. (2004). "Serious bacterial infections in febrile infants 1 to 90 days old with and without viral infections." *Pediatrics* 113(6): 1662-1666.
7. King, R. L., et al. (2007). "Routine cerebrospinal fluid enterovirus polymerase chain reaction testing reduces hospitalization and antibiotic use for infants 90 days of age or younger." *Pediatrics* 120(3): 489-496.
8. Dewan, M., et al. (2010). "Cerebrospinal fluid enterovirus testing in infants 56 days or younger." *Arch Pediatr Adolesc Med* 164(9): 824-830.
9. Wallace, S. S., et al. (2017). "Impact of Enterovirus Testing on Resource Use in Febrile Young Infants: A Systematic Review." *Hosp Pediatr* 7(2): 96-102.
10. Pantell RH, Newman TB, Bernzweig J, Bergman DA, et al. Management and outcomes of care of fever in early infancy. *Jama*. 2004;291(10):1203-12. <http://proxygw.wrlc.org/login?url=https://search-proquest-com.proxygw.wrlc.org/docview/211388160?accountid=11243>.
11. Mintegi S, Gomez B, Martinez-Virumbrales L, Morientes O, Benito J. Outpatient management of selected young febrile infants without antibiotics. *Arch Dis Child*. 2017;102(3):244. <http://proxygw.wrlc.org/login?url=https://search-proquest-com.proxygw.wrlc.org/docview/1873331670?accountid=11243>. doi: <http://dx.doi.org.proxygw.wrlc.org/10.1136/archdischild-2016-310600>.
12. Maniaci V, Dauber A, Weiss S, Nylan E, Becker KL, Bachur R. Procalcitonin in young febrile infants for the detection of serious bacterial infections. *Pediatrics*. 2008;122(4):701-n/a. <http://proxygw.wrlc.org/login?url=https://search-proquest-com.proxygw.wrlc.org/docview/228323532?accountid=11243>. Milcent K, Faesch S, Gras-Le Guen C, et al. Use of Procalcitonin Assays to Predict Serious Bacterial Infection in Young Febrile Infants. *JAMA Pediatr* 2016; 170:62.
13. Caviness AC, Demmler GJ, Selwyn BJ. Clinical and laboratory features of neonatal herpes simplex virus infection: a case-control study. *Pediatr Infect Dis J* 2008;27:425-30.
14. Whitley R, Arvin A, Prober C, et al. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. *N Engl J Med* 1991;324:450-4.
15. Levine DA, Platt SL, Dayan PS, Macias CG, et al. Risk of serious bacterial infection in young febrile infants with respiratory syncytial virus infections. *Pediatrics*. 2004;113(6):1728-34. <http://proxygw.wrlc.org/login?url=https://search-proquest-com.proxygw.wrlc.org/docview/228418980?accountid=11243>.
16. Jantausch B, Kher KK. Clinical pediatric nephrology. In: Kher KK, Schnaper HW, Makker SP, Makker SP, editors. *Urinary tract infection*. 2nd ed. London: Informa Healthcare; 2006. pp. 553-73.
17. Neuhaus TJ, Berger C, Buechner K, Parvex P, Bischoff G, Goetschel P, et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. *Eur J Pediatr*. 2008;167(9):1037-47
18. Baker MD, Bell LM, Avner JR. The efficacy of routine outpatient management without antibiotics of fever in selected infants. *Pediatrics* 1999;103:627-31.
19. Management of infants and young children with fever without source. Baraff LJ. *Pediatr Ann*. 2008 Oct;37(10):673-9.
20. Management of the Febrile Young Infant: Update for the 21st Century. Woll C, Neuman MI, Aronson PL. *Pediatr Emerg Care*. 2017 Nov;33(11):748-753. doi: 10.1097/PEC.0000000000001303.


CLINICAL IMPROVEMENT TEAM MEMBERS

Sarah Schmidt, MD | Emergency Medicine
Kaitlin Widmer, MD | Pediatric Hospitalist
Lalit Bajaj, MD | Emergency Medicine
Leigh Anne Bakel, MD | Pediatric Hospitalist
Sharisse Arnold-Rehring, MD | Kaiser
Nicole Clifton, MD | Pediatric Resident
Lee Engelbreath, MD | Kaiser
Jason French, MD | Pediatric Hospitalist
James Gaensbauer, MD | Infectious Disease
Theresa Grover, MD | Neonatal Intensivist
Andrew Haynes, MD | Infectious Disease, Fellow
Satya Houin, MD | Neonatal Intensivist

Joni Mackenzie, PNP | Emergency Medicine
Kevin Messacar, MD | Infectious Disease
Rakesh Mistry, MD | Emergency Medicine
Sean O’Leary, MD | Infectious Disease
Suchitra Rao, MD | Infectious Disease
Kathryn Rappaport, MD | EM, Fellow
Emma Ross, PharmD | NICU Pharmacist
Irina Topoz, MD | Emergency Medicine
Amy Willis, MD | Pediatric Hospitalist
Julie Michie, MD | Emergency Medicine
Kaylee Wickstrom, RN, Process Improvement Specialist | Clinical Effectiveness

APPROVED BY

Clinical Care Guideline and Measures Review Committee – January 9th, 2018
 Pharmacy and Therapeutics Committee – February 1st, 2018

MANUAL/DEPARTMENT	Clinical Care Guidelines/Quality
ORIGINATION DATE	December 6, 2012
LAST DATE OF REVIEW OR REVISION	February 1, 2018
APPROVED BY	 Lalit Bajaj, MD, MPH Medical Director, Clinical Effectiveness

REVIEW/REVISION SCHEDULE

Scheduled for full review on February 1, 2022.

Clinical pathways are intended for informational purposes only. They are current at the date of publication and are reviewed on a regular basis to align with the best available evidence. Some information and links may not be available to external viewers. External viewers are encouraged to consult other available sources if needed to confirm and supplement the content presented in the clinical pathways. Clinical pathways are not intended to take the place of a physician’s or other health care provider’s advice, and is not intended to diagnose, treat, cure or prevent any disease or other medical condition. The information should not be used in place of a visit, call, consultation or advice of a physician or other health care provider. Furthermore, the information is provided for use solely at your own risk. CHCO accepts no liability for the content, or for the consequences of any actions taken on the basis of the information provided. The information provided to you and the actions taken thereof are provided on an “as is” basis without any warranty of any kind, express or implied, from CHCO. CHCO declares no affiliation, sponsorship, nor any partnerships with any

Discrimination is Against the Law. Children's Hospital Colorado complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Children's Hospital Colorado does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex.

Children's Hospital Colorado provides free aids and services to people with disabilities to communicate effectively with us, such as: Qualified sign language interpreters, written information in other formats (large print, audio, accessible electronic formats, other formats). Children's Hospital Colorado provides free language services to people whose primary language is not English, such as: Qualified interpreters, information written in other languages.

If you need these services, contact the Medical Interpreters Department at 720.777.9800.

If you believe that Children's Hospital Colorado has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with: Corporate Compliance Officer, 13123 E 16th Avenue, B450, Aurora, Colorado 80045, Phone: 720.777.1234, Fax: 720.777.7257, corporate.compliance@childrenscolorado.org. You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Corporate Compliance Officer is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at: U.S. Department of Health and Human Services 200 Independence Avenue, SW Room 509F, HHH Building Washington, D.C. 20201 1-800-368-1019, 800-537-7697 (TDD) Complaint forms are available at www.hhs.gov/ocr/office/file/index.html.

Children's Hospital Colorado complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex.

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1-720-777-9800.

CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 1-720-777-9800.

주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 1-720-777-9800 번으로 전화해 주십시오.

注意: 如果您使用繁體中文, 您可以免費獲得語言援助服務。請致電1-720-777-9800。

ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 1-720-777-9800.

ማስታወሻ: የሚናገሩት ቋንቋ አማርኛ ከሆነ የትርጉም አርዳታ ድርጅቶቹ: በነጻ ሊያግዝዎት ተዘጋጅተዋል። ወደ ሚስተለው ቁጥር ይደውሉ 1-720-777-9800 (መስማት ለተሳናቸው)።

ملحوظة: إذا كنت تتحدث انكر اللغة، فإن خدمات المساعدة اللغوية تتوافر لك بالمجان. اتصل برقم 1-720-777-9800.

ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 1-720-777-9800.

ATTENTION : Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 1-720-777-9800.

ध्यान दनु होस्त्पाइले नेपाल बोलनहनछ भन तपाइको निम्त भाषा सहायता सवाहरूनःशुलक रूपमा उपलब्ध छ । फोन गनु होसरू 1-720-777-9800 ।

PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 1-720-777-9800.

注意事項: 日本語を話される場合、無料の言語支援をご利用いただけます。1-720-777-9800 まで、お電話にてご連絡ください。

Nti: O buri na asụ Ibo, asụsụ aka oasụ n'efu, defu, aka. Call 1-720-777-9800.